𝔖 Bobbio Scriptorium
✦   LIBER   ✦

P666 PREDICTORS OF SEVERE HEPATIC FIBROSIS IN TREATMENT-NAIVE GENOTYPE B OR C INFECTED E ANTIGEN-POSITIVE AND -NEGATIVE CHRONIC HEPATITIS B PATIENTS

✍ Scribed by Su, W.-P.; Peng, C.-Y.; Lai, H.-C.; Lin, C.-H.; Chuang, P.-H.; Chen, S.-H.

Book ID
122332011
Publisher
Elsevier Science
Year
2014
Tongue
English
Weight
175 KB
Volume
60
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60